Illumina Inc, San Diego, has agreed to process more than 6,500 samples for researchers of the Type 1 Diabetes Genetics Consortium (T1DGC) via its FastTrack genotyping services.
With financial support from the National Institute of Diabetes and Digestive and Kidney Diseases, the T1DGC will attempt to identify genes that influence an individual’s risk for developing Type 1 diabetes.
Principal Investigator Stephen Rich, PhD, from the University of Virginia and chair of the T1DGC steering committee, has chosen to use Illumina’s new HumanHap550-Duo BeadChip for the study.
After the genes are identified, researchers plan to use the information to develop enhanced approaches to detecting, treating, and preventing the disease.
Illumina‘s FastTrack Genotyping Services group has processed more than 300,000 samples and generated more than 18 billion genotypes, helping researchers worldwide to identify genes linked to a number of complex diseases, including psychological disorders, asthma, and cancer.
